EU signs joint procurement deal for Eli Lilly COVID-19 treatment
Reuters
Published Sep 21, 2021 19:55
BRUSSELS (Reuters) - The European Commission has signed a joint procurement contract with U.S. drugmaker Eli Lilly (NYSE:LLY) and Co for the supply of a monoclonal antibody treatment for COVID-19, the EU executive arm said in a statement on Tuesday.
The treatment is under review by the European Medicines Agency, it said, and 18 EU countries have signed up to the joint procurement for the purchase of enough to treat up to 220,000 patients.
The deal is part of a portfolio of five promising therapeutics announced by the Commission under the EU's COVID-19 Therapeutics Strategy in June. It also includes treatments from GlaxoSmithKline Plc and Vir Biotechnology Inc, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Celltrion HealthCare Co.
"We need to continue our work to prevent illness with vaccines and at the same time ensure that we can treat it with therapeutics," EU Commissioner for Health Stella Kyriakides said.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.